John Somberg, Chicago, IL (US); Brandon Ira Kashfian, Chicago, IL (US); and Janos Molnar, Chicago, IL (US)
Assigned to AltaThera Pharmaceuticals LLC, Chicago, IL (US)
Filed by AltaThera Pharmaceuticals LLC, Chicago, IL (US)
Filed on Apr. 20, 2022, as Appl. No. 17/725,189.
Application 17/725,189 is a continuation of application No. 16/946,941, filed on Jul. 13, 2020, granted, now 11,344,518.
Application 16/946,941 is a continuation in part of application No. 16/863,567, filed on Apr. 30, 2020, abandoned.
Application 16/946,941 is a continuation in part of application No. 16/693,310, filed on Nov. 24, 2019, granted, now 11,696,902.
Application 16/863,567 is a continuation in part of application No. 16/103,815, filed on Aug. 14, 2018, granted, now 10,512,620, issued on Dec. 24, 2019.
Application 16/863,567 is a continuation in part of application No. 16/693,312, filed on Nov. 24, 2019.
Application 16/693,312 is a continuation of application No. 16/103,815, filed on Aug. 14, 2018, granted, now 10,512,620, issued on Dec. 24, 2019.
Application 16/946,941 is a continuation in part of application No. 16/849,099, filed on Apr. 15, 2020, abandoned.
Claims priority of provisional application 63/009,511, filed on Apr. 14, 2020.
Claims priority of provisional application 62/987,832, filed on Mar. 10, 2020.
Prior Publication US 2022/0241225 A1, Aug. 4, 2022
1. A method of administering sotalol hydrochloride, comprising:
a. administering an intravenous (IV) dose of 125-135 mg sotalol hydrochloride over a period of 1 hour to a subject having had symptomatic atrial fibrillation or atrial flutter, wherein the subject is currently in sinus rhythm; and
b. after completion of the IV dose, administering oral dosing of one or more oral dose of sotalol hydrochloride to the subject in an amount of 120 mg.